全球的神經調節機器市場展望：2011-2021年 是由出版商Visiongain在2011年10月所出版的。
這份英文市場調查報告書包含127 Pages 價格從美金2642起跳。
神經調節機器、在醫療機器市場中是最急速擴大的領域之一。神經調節療法為神經系統功能的調整或透過調節減輕症狀的醫療技術、有急速的發展。那是、刺激神經所衍生出來的自然性生物學反應、或是作用部位直接投入少量的醫藥品。2011年在神經調節機器的全球市場中、30億5,000萬美金的規模為Visiongain的預測。
本報告書內容包括:全球的神經調節機器市場為焦點、最新的市場趨勢彙整、2021年為止的全球、地區分類、及各次級市場（脊髄電氣刺激（SCS）、腦深部刺激（DBS）、及迷走神經刺激（VNS）機器）的市場預測之提示、市場的SWOT分析及新事業機會的相關分析等彙整、內容綱要摘記如下:
第1章 實施摘要
第2章 神經調節的介紹
- 神經調節
- 神經調節所使用的療法
- 神經調節應用
- 痛苦
- 憂鬱症
- 癲癇
- 泌尿器系障礙：過活動膀胱及尿失禁
- 聽覺障礙：高度重聽
- 心疾病：心律不整及狭心症
- 帕金森氏症
第3章 全球的神經調節機器市場：2010-2021年
- 範圍及制約
- 神經調節機器在神經系統醫療機器領域中為最大分類
- 神經調節機器市場：2010年
- 神經調節機器市場的主要領導為Medtronic
- 市場的神經調節機器
- 神經調節機器市場的主要企業：2010年
- Medtronic：2010年銷售額、市場的DBS及SCS機器、產品供給路徑
- St. Jude Medical（SJM）：2010年銷售額、市場的神經調節機器、產品供給路徑
- Boston Scientific：2010年銷售額、市場的神經調節機器、販賣及供給路徑
- Cyberonics：2010年銷售額、神經調節機器、販賣及供給路徑
- IntraPace
- 神經調節機器市場的預測：2011-2016年
- 神經調節機器市場的預測：2016-2021年
- 變化的主要分類市場佔有率
第4章 脊髄電氣刺激（SCS）機器市場：2010-2021年
- 2010年SCS機器市場：美國為最大市場
- 美國SCS機器市場中Medtronic占優越、之後SJM及Boston Scientific緊追在後
- SCS機器市場的預測：2011-2016年
- SCS機器市場的預測：2016-2021年
- SCS機器市場的競爭：企業及產品
- Medtronic
- Boston Scientific
- St. Jude Medical
- Nevro
第5章 腦深部刺激（DBS）機器市場：2010-2021年
- 2010年的DBS機器市場：Medtronic為美國FDA（食品醫藥品局）認定DBS機器保有的唯一企業
- DBS機器市場的預測：2011-2016年
- DBS機器市場的預測：2016-2021年
- DBS機器市場的競爭：企業及產品
- Medtronic
- St. Jude Medical
第6章 迷走神經刺激（VNS）機器市場：2010-2021年
- 2010年的VNS市場：美國占市場銷售的81.3%
- 2010年的VNS機器銷售的大部分為難治性癲癇治療用
- 2010年有Cyberonics為VNS市場的優越
- VNS機器市場的預測：2011-2016年
- VNS機器市場的預測：2016-2021年
- VNS機器市場的競爭：企業及產品
- Cyberonics
- CerebralRx（BioControl Medical的分割企業）
- EnteroMedics
第7章 神經調節機器的供給路徑
- CVRx
- Apnex Medical
- ImThera Medical
- NeuroPace
- Intelect Medical（收購Boston Scientific Corporation）
- EnteroMedics
- MetaCure
- 其他企業及產品
第8章 主要國家市場：2010-2021年
- 主要國家市場：2010年
- 美國市場的預測：2011-2021年
- 日本市場的預測：2011-2021年
- 主要的歐洲市場的預測：2011-2021年
- 德國市場
- 法國市場
- 英國市場
- 義大利市場
- 西班牙市場
- 中國市場的預測：2011-2021年
- 印度市場的預測：2011-2021年
- 全球的其他地區（RoW）
第9章 神經調節機器產業的SWOT分析：2011-2021年
第10章 專家的見解
- Michael Berman先生（Berman Medical的創立者）的訪問
- CVRx的發言人（匿名的意見提供）
- NeuroPace Inc的Franck Fischer先生（CEO）及Rebecca Kuhn先生（CFO）
第11章 結論
- 神經調節機器市場由4家獨佔
- 神經調節機器市場：2011-2021年
- 神經調節機器推動新的適應症開發：市場成長的促進
- 新興市場的大成長機會
- 替代性治療附加選項的引進對市場成長的威脅
附錄A
附錄B
Visiongain報告書評價型式
圖表
Abstract
Our latest pharma report - Neuromodulation Devices: World Market Prospects
2011-2021 - offers a comprehensive view of the global neuromodulation devices
market. The report analyses recent trends in this market and anticipates the
progression in the market over the next decade with global, regional and
submarket forecasts. The report also reveals the market's strengths and
weaknesses revealing areas that will experience growth and present new
business opportunities. Visiongain analyses predict the global value of the
neuromodulation devices market in 2011 to be worth $3.05bn. The market has
significant potential for growth with the increasing global burden of
neurological and cardiovascular disorders, especially in the emerging
economies. Growth in this market will also be driven by the approval and
launch of neuromodulation devices that are more effective and involve a more
simplified, less-invasive implantation procedure.
Neuromodulation is one of the fastest growing sectors of the medical device
market. Neuromodulation is a rapidly evolving medical technique that provides
symptomatic relief through the alteration, or modulation, of nerve system
function. It works by either stimulating nerves to produce a natural
biological response or by applying small doses of pharmaceutical agents
directly to the site of action.
Visiongain's research suggests that the neuromodulation devices market will
benefit from the growth of healthcare markets in the emerging economies. The
growth in emerging markets such as India and China will be driven by an aging
population that will increase demand for newer treatment options for
age-related diseases. India's expanding economy is likely to see an increased
wealth among the population, specifically within the middle class, which will
cause an increased adoption of westernised lifestyles. Diseases such as
obesity and coronary heart disease will therefore become more prevalent. The
neuromodulation devices market in the emerging economies will also benefit
from a rise in demand for non-invasive treatment options and medical tourism.
The Neuromodulation Devices: World Market Prospects 2011-2021 examines the
spinal cord stimulaiton, deep brain stimulation and vagus nerve stimulation
with respect to the market size, leading companies and products, and promising
products in the pipeline. Visiongain predicts that this market will grow
steadily to 2021, primarily driven by a rise in age-related diseases, approval
of innovative devices, and increased patient adoption of existing and
newly-marketed products.
How will the neuromodulation devices market develop this decade? Which regions
offer the most significant growth opportunities between 2011 and 2021? Which
of the neuromodulation devices submarkets are growing most strongly? Who are
the leading companies in the neuromodulation devices market? What are the most
promising neuromodulation devices in development and when are they expected to
receive market approval?
Visiongain answers these critical questions and many more through the in-depth
analyses that are presented in this report.
Detailed analysis of the global Neuromodulation Devices Market
Neuromodulation Devices: World Market Prospects 2011-2021 examines that sector
critically, through a comprehensive review of information sources, both
primary and secondary. This report provides detailed sales forecasts, market
share analyses, discussions of pipeline developments and analyses of
commercial drivers and restraints, including SWOT analysis. There are 93
tables and figures included, as well as two full interviews with relevant
authorities. The result is a comprehensive market- and industry-centred study,
with detailed analyses and informed opinion to benefit your work.
Why you should buy Neuromodulation Devices: World Market Prospects 2011-2021
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for neuromodulation
devices, with respect to the leading segments, products, companies and
national markets
- You will discover sales trends for the overall neuromodulation devices
market from 2011 to 2021 - seeing where commercial growth will occur
- You will discover sales trends for the main segments - spinal cord
stimulation, deep brain stimulation and vagus nerve stimulation - from 2011 to
2021, with detailed discussions of market potential
- You will receive sales forecasts for leading geographical markets (US,
Japan, Germany, France, Italy, Spain, UK, China and India), with informed
discussion
- You will assess leading companies in the neuromodulation devices market
along with their marketed and pipeline products
- You will receive our analyses of the future of neuromodulation devices
market, including assessment of some products in the R&D pipeline
- You will examine the strengths, weaknesses, opportunities and threats
(SWOT analysis) facing the neuromodulation devices markets from 2011 onwards
- You will be able to investigate competition and opportunities influencing
the neuromodulation devices market from 2011 onwards
- You will see what will stimulate and restrain the neuromodulation devices
market from 2011
- You will discover the unmet needs in the market, driving the growth from
2011 onwards
- You will view expert opinion from our survey, including full interview
transcripts.
You can obtain this report today
Anybody with an interest in the neuromodulation/neurostimulation devices
industry should gain valuable information and insight from this new study by
Visiongain, which analyses one of the most important neurological devices
industries. Success in the neurological devices market from 2011 to 2021 will
be characterised by the growth of neuromodulation devices market and launch of
innovative products currently in the pipeline. You can find out about the
developments in this industry and much more from this latest report from
visiongain on Neuromodulation Devices: World Market Prospects 2011-2021. You
can stay ahead by ordering this report today.
Visiongain is a trading partner with the US Federal Government.
Table of Contents
1. Executive Summary
- 1.1. Sector Highlights
- 1.2. Aims, Scope and Format of the Report
- 1.3. Research and Analysis Methods
- 1.4. Glossary of Terms Related to Neuromodulation Devices
2. An Introduction to Neuromodulation
- 2.1. Neuromodulation
- 2.2. Techniques Used in Neuromodulation
- 2.2.1. Electrical Stimulation Techniques
- 2.2.1.1. Brain and Spinal Cord Therapies
- 2.2.1.2. Cranial Nerve Stimulation
- 2.2.1.3. Functional Electrical Stimulation
- 2.2.2. Pharmacological Therapy
- 2.3. Application of Neuromodulation
- 2.3.1. Pain
- 2.3.1.1. Neuromodulation and Treatment of Pain
- 2.3.2. Depression
- 2.3.2.1. Neuromodulation and Treatment of Depression
- 2.3.3. Epilepsy
- 2.3.3.1. Neuromodulation and Treatment of Epilepsy
- 2.3.4. Urological Disorders: Overactive Bladder & Urinary Incontinence
- 2.3.4.1. SNS and Treatment of Urinary Incontinence
- 2.3.5. Hearing Disorders: Profound Deafness
- 2.3.6. Cardiac Disorders: Arrhythmias & Angina
- 2.3.6.1. Neuromodulation and Treatment of Cardiac Disorders
- 2.3.7. Parkinson's Disease
3. The Global Neuromodulation Devices Market, 2010-2021
- 3.1. Scope and Limitations
- 3.2. Neuromodulation Devices is the Largest Segment in the Neurological
Medical Devices Sector
- 3.3. Neuromodulation Devices Market in 2010
- 3.3.1. SCS Devices Dominate the Neuromodulation Devices Market in 2010
- 3.4. Medtronic is the Market Leader in the Neuromodulation Devices Market
- 3.5. Neuromodulation Devices in the Market
- 3.6. Leading Companies in the Neuromodulation Devices Market, 2010
- 3.6.1. Medtronic
- 3.6.1.1. Medtronic Sales, 2010
- 3.6.1.2. Medtronic's DBS and SCS Devices in the Market
- 3.6.1.3. Medtronic's Product Pipeline
- 3.6.2. St. Jude Medical (SJM)
- 3.6.2.1. SJM Sales, 2010
- 3.6.2.2. SJM Neuromodulation Devices in the Market
- 3.6.2.3. SJM Product Pipeline
- 3.6.3. Boston Scientific
- 3.6.3.1. Boston Scientific Sales, 2010
- 3.6.3.2. Boston Scientific Neuromodulation Devices: Marketed and
Pipeline
- 3.6.4. Cyberonics
- 3.6.4.1. Cyberonics Sales, 2010
- 3.6.4.2. Cyberonics Neuromodulation Devices: Marketed and Pipeline
- 3.6.5. IntraPace
- 3.7. Neuromodulation Devices Market Forecast, 2011-2016
- 3.8. Neuromodulation Devices Market Forecast, 2016-2021
- 3.9. Changing Market Shares of the Leading Segments
4. Spinal Cord Stimulation Devices Market, 2010-2021
- 4.1. The US was the Largest Market for SCS Devices in 2010
- 4.2. Medtronic Dominated the US SCS Devices Market, Closely Followed by
SJM and Boston Scientific
- 4.3. SCS Devices Market Forecast, 2011-2016
- 4.4. SCS Devices Market Forecast, 2016-2021
- 4.5. Competition in the SCS Market: Companies and Products
- 4.5.1. Medtronic
- 4.5.2. Boston Scientific
- 4.5.3. St. Jude Medical
- 4.5.4. Nevro
5. Deep Brain Stimulation Devices Market, 2010-2021
- 5.1. DBS Devices Market in 2010: Medtronic is the Only Company With an FDA
Approved DBS Device
- 5.2. DBS Devices Market Forecast, 2011-2016
- 5.3. DBS Devices Market Forecast, 2016-2021
- 5.4. Competition in the DBS Devices Market: Companies and Products
- 5.4.1. Medtronic
- 5.4.2. St. Jude Medical
6. Vagus Nerve Stimulation Devices Market, 2010-2021
- 6.1. The US Contributed 81.3% of the VNS Market Sales in 2010
- 6.2. Majority of Sales of the VNS Devices Was for the Treatment of
Refractory Epilepsy in 2010
- 6.3. Cyberonics Dominated the VNS Market in 2010
- 6.3.1. Cyberonics is Set to Lose its Monopoly in the VNS Devices Market
- 6.4. VNS Devices Market Forecast, 2011-2016
- 6.5. VNS Devices Market Forecast, 2016-2021
- 6.6. Competition in the VNS Devices Market: Companies and Products
- 6.6.1. Cyberonics
- 6.6.2. CerebralRx (a spin-off of BioControl Medical)
- 6.6.3. EnteroMedics
7. Neuromodulation Devices Pipeline
- 7.1. CVRx
- 7.2. Apnex Medical
- 7.3. ImThera Medical
- 7.4. NeuroPace
- 7.5. Intelect Medical (acquired by Boston Scientific Corporation)
- 7.6. EnteroMedics
- 7.7. MetaCure
- 7.8. Other Companies and Products
8. Leading National Markets, 2010-2021
- 8.1. Leading National Markets in 2010
- 8.2. The US Market Forecast, 2011-2021
- 8.3. The Japanese Market Forecast, 2011-2021
- 8.4. Leading European Markets Forecast, 2011-2021
- 8.4.1. The German Market
- 8.4.2. The French Market
- 8.4.3. The UK Market
- 8.4.4. The Italian Market
- 8.4.5. The Spanish Market
- 8.5. The Chinese Market Forecast, 2011-2021
- 8.6. The Indian Market Forecast, 2011-2021
- 8.7. Rest of the World (RoW)
9. SWOT Analysis of the Neuromodulation Device Industry, 2011-2021
- 9.1. Strengths
- 9.1.1. Neuromodulation Can be Seen as Safer Than Alternative Treatments
- 9.1.2. A Cost Effective Treatment Option
- 9.1.3. Neuromodulation Often Means Less Medication
- 9.2. Weaknesses
- 9.2.1. Neuromodulation Mechanisms Are Not Well Understood
- 9.2.2. A Small Number of Large Companies Dominate the Market
- 9.2.3. FDA Approvals
- 9.2.4. Failing Clinical Trials
- 9.3. Opportunities
- 9.3.1. Neuromodulation Market Set for Rapid Growth: Expanding Disease
Indications
- 9.3.2. Increasing Prevalence of Neurological Diseases
- 9.3.3. The Potential of Personalised Medicine
- 9.4. Threats
- 9.4.1. Parkinson's Disease May Soon be Treated with Stem Cells
- 9.4.2. SCS Faces Competition from Other Treatment Options
10. Expert Opinion
- 10.1. Interview with Michael Berman, Founder, Berman Medical
- 10.1.1. The Neuromodulation Market
- 10.1.2. Challenges Facing the Neuromodulation Market
- 10.1.3. Prospects for the Neuromodulation Market
- 10.2. Spokesperson from CVRx (Views Provided Anonymously)
- 10.2.1. Barostim neo: New Implantable Device for Hypertension
- 10.2.2. On the Development of Barostim neo
- 10.2.3. Competition for Barostim neo
- 10.2.4. On the Unmet Needs in the Market
- 10.3. Franck Fischer and Rebecca Kuhn, CEO and CFO, NeuroPace Inc
- 10.3.1. NeuroPace's RNS Neuromodulation System for Epilepsy
- 10.3.2. The Neuromodulation and the Epilepsy Markets
- 10.3.3. Public Perception and Understanding of Neuromodulation
- 10.3.4. Small Companies Surviving in the Industry
- 10.3.5. Educating Physicians About Neuromodulation
- 10.3.6. Neuromodulation's Role in Relation to Other Treatment Options
- 10.3.7. Recent Healthcare Reform in the US
- 10.3.8. Comparative Effectiveness Research
11. Conclusions
- 11.1. The Neuromodulation Devices Market is Dominated by Four Companies
- 11.2. The Neuromodulation Devices Market, 2011-2021
- 11.3. Neuromodulation Devices Will be Developed for New Indications:
Driving Market Growth
- 11.4. Vast Opportunities for Growth in Emerging Markets
- 11.5. Introduction of Alternative Treatment Options Can Threaten Market
Growth
Appendix A
Appendix B
Visiongain report evaluation form
List of Tables
- Table 3.1: The Neurological Devices Market: Sales ($bn) and Market Share
(%) by Sectors, 2010
- Table 3.2: Global Neuromodulation Devices Market by Leading Segments:
Sales ($bn) and Market Share (%), 2010
- Table 3.3: Global Neuromodulation Devices Market ($m) by Company, 2010
- Table 3.4: List of Some Approved/Marketed Neuromodulation Devices, 2011
- Table 3.5: Medtronic Sales ($bn) by Business Segment, 2010 and 2009
- Table 3.6: St. Jude Medical Sales ($bn) by Business Segment, 2010
- Table 3.7: Boston Scientific Sales ($bn) by Business Segment, 2010
- Table 3.8: Neuromodulation Devices Market: Sales Forecast ($bn), 2010-2016
- Table 3.9: Neuromodulation Devices Market: Sales Forecast ($bn), 2016-2021
- Table 3.10: Market Shares (%) of Leading Segments in the Neuromodulation
Devices Market, 2010, 2016 & 2021
- Table 4.1: SCS Devices Market: Regional Sales ($bn), 2010
- Table 4.2: The US SCS Devices Market by Leading Companies ($m), 2010
- Table 4.3: SCS Devices Market: Sales Forecast ($bn), 2010-2016
- Table 4.4: SCS Devices Market: Sales Forecast ($bn), 2016-2021
- Table 5.1: DBS Devices Market: Sales Forecast ($bn), 2010-2016
- Table 5.2: DBS Devices Market: Sales Forecast ($bn), 2016-2021
- Table 6.1: VNS Devices Market: Regional Sales ($m), 2010
- Table 6.2: VNS Devices Market ($m) by Indication, 2010
- Table 6.3: Cyberonics' VNS Therapy System: Unit Sales by Indication, 2010
- Table 6.4: VNS Devices Market: Sales Forecast ($bn), 2010-2016
- Table 6.5: VNS Devices Market: Sales Forecast ($bn), 2016-2021
- Table 7.1: Neuromodulation Devices Pipeline, 2011
- Table 7.2: Other Companies Involved in the Development of Neuromodulation
Devices, 2011
- Table 8.1: Leading National Markets: Sales ($bn) & Market Shares (%), 2010
- Table 8.2: The US Neuromodulation Devices Market Forecast ($bn), 2010-2016
- Table 8.3: The US Neuromodulation Devices Market Forecast ($bn), 2016-2021
- Table 8.4: The Japanese Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.5: The Japanese Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.6: The German Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.7: The German Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.8: The French Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.9: The French Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.10: The UK Neuromodulation Devices Market Forecast ($bn), 2010-2016
- Table 8.11: The UK Neuromodulation Devices Market Forecast ($bn), 2016-2021
- Table 8.12: The Italian Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.13: The Italian Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.14: The Spanish Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.15: The Spanish Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.16: The Chinese Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.17: The Chinese Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.18: The Indian Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Table 8.19: The Indian Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Table 8.20: Rest of the World Neuromodulation Devices Market Forecast
($bn), 2010-2016
- Table 8.21: Rest of the World Neuromodulation Devices Market Forecast
($bn), 2016-2021
- Table 9.1: SWOT Analysis of the Neuromodulation Devices Market, 2011-2021
List of Figures
- Figure 3.1: World Neuromodulation Devices Market Share (%) in the
Neurological Devices Market, 2010
- Figure 3.2: Market Shares (%) of Leading Segments in the Neuromodulation
Devices Market, 2010
- Figure 3.3: The Neuromodulation Devices Market ($bn) by Segments, 2010
- Figure 3.4: Market Shares (%) of Leading Companies in the Global
Neuromodulation Devices Market, 2010
- Figure 3.5: Medtronic Sales Share (%) by Business Segment, 2010
- Figure 3.6: St Jude Medical Sales Share (%) by Business Segment, 2010
- Figure 3.7: Boston Scientific Sales Share (%) by Business Segment, 2010
- Figure 3.8: Neuromodulation Devices Market: Sales Forecast ($bn), 2010-2016
- Figure 3.9: Neuromodulation Devices Market: Sales Forecast ($bn), 2016-2021
- Figure 3.10: Market Shares (%) of Leading Segments in the Neuromodulation
Devices Market, 2016
- Figure 3.11: Market Shares (%) of Leading Segments in the Neuromodulation
Devices Market, 2021
- Figure 4.1: SCS Devices Market Share (%) by Regions, 2010
- Figure 4.2: Market Shares (%) of Leading Companies in the US SCS Devices
Market, 2010
- Figure 4.3: SCS Devices Market: Sales Forecast ($bn), 2010-2016
- Figure 4.4: SCS Devices Market: Sales Forecast ($bn), 2016-2021
- Figure 5.1: DBS Devices Market: Sales Forecast ($bn), 2010-2016
- Figure 5.2: DBS Devices Market: Sales Forecast ($bn), 2016-2021
- Figure 6.1: VNS Devices Market Share (%) by Regions, 2010
- Figure 6.2: VNS Devices Market Share (%) by Indication, 2010
- Figure 6.3: Cyberonics' VNS Therapy System Units Market Share (%) by
Indication, 2010
- Figure 6.4: VNS Devices Market: Sales Forecast ($bn), 2010-2016
- Figure 6.5: VNS Devices Market: Sales Forecast ($bn), 2016-2021
- Figure 8.1: Leading National Markets: Market Shares (%), 2010
- Figure 8.2: The US Neuromodulation Devices Market Forecast ($bn), 2010-2016
- Figure 8.3: The US Neuromodulation Devices Market Forecast ($bn), 2016-2021
- Figure 8.4: The Japanese Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.5: The Japanese Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.6: The German Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.7: The German Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.8: The French Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.9: The French Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.10: The UK Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.11: The UK Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.12: The Italian Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.13: The Italian Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.14: The Spanish Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.15: The Spanish Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.16: The Chinese Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.17: The Chinese Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.18: The Indian Neuromodulation Devices Market Forecast ($bn),
2010-2016
- Figure 8.19: The Indian Neuromodulation Devices Market Forecast ($bn),
2016-2021
- Figure 8.20: Rest of the World Neuromodulation Devices Market Forecast
($bn), 2010-2016
- Figure 8.21: Rest of the World Neuromodulation Devices Market Forecast
($bn), 2016-2021
Companies Listed Advanced Bionics
- Advanced Neuromodulation Systems (ANS)
- Aleva Neurotherapeutics
- AMS group
- Apnex Medical
- Atrotech
- Australian Therapeutic Goods Administration (TGA)
- Autonomic Technologies
- Avery Biomedical
- Berman Medical
- BioControl Medical
- Biotronik
- Boston Scientific
- Cardiac Concepts
- Cerbomed
- CerebralRx
- Cochlear Ltd.
- Coridea
- CVRx
- Cyberonics
- DePuy
- EBR Systems
- ElectroCore
- EnteroMedics
- Envoy Medical
- Eucomed
- European Commission (EC)
- Food and Drug Administration (FDA)
- Functional Neuromodulation
- ImThera Medical
- Inspire Medical Systems
- Intelect Medical
- International Neuromodulation Society
- IntraPace
- Johnson & Johnson (J&J)
- Magstim
- Med El
- Medtronic
- MetaCure
- MicroTransponder
- Nanoretina Inc.
- National Epilepsy Foundation
- Neurelec
- Neurologix
- Neuronetics
- NeuroPace
- Neuros Medical
- Neurosigma
- Neurotech
- Neurowave Medical Technologies
- Nevro
- Nihon Kohden Corporation
- Northstar Neuroscience
- Northwestern University
- Respicardia
- Retina Implant AG
- Second Sight Medical Products
- Setpoint Medical
- Spinal Modulation
- SPR Therapeutics
- St. Jude Medical
- Synapse Biomedical
- The International Neuromodulation Society
- Transneuronix
- Uroplasty
- U.S. Centers for Disease Control (CDC)
- World Health Organization
預計2021年全球神經調節機器市場將達到116億1,000萬美元
2011年12月19日
Global Information, Inc.已開始銷售Visiongain所發行的報告書「Neuromodulation Devices: World Market Prospects 2011-2021 (全球的神經調節機器市場展望：2011-2021年)」
Visiongain的本報告書預測全球神經調節機器市場於2021年時將達到116億1,000萬美元規模。2010年該市場的銷售額是27億美元。
神經調節療法是迅速進化的醫療技術，透過標的傳遞或電力刺激來改善病情。
此療法是將小型電力裝置或藥劑幫浦，透過外科手術埋藏在體內。
而且，脈衝發生器發出電力的信號，透過電極線來引起生物學的反應或使少量的治療藥在作用部位釋放出。
此技術已被承認可使用在運動性疾病、精神性疾病、慢性痛等，現在為了亦能應用到肥胖症、偏頭痛、心力衰竭等其他疾病，正繼續進行研究中。
神經調節機器市場現在的規模尚小，非新興市場，然是醫療機器市場最迅速成長的部門。
醫療業界分析家Hemant Mistry敘述：「神經調節機器市場今後將穩健成長。隨著年齡增加而疾病增加，創新的醫療機器獲得認可，以及原有和採用新機器的患者增加成為其背景。神經調節治療作為患者治療時可供選擇的方案，雖非是新的方案，然現今終於變成聚集關心的場所。對病理學介入（高水平的副作用和過敏），患者不滿增加已成為主因。」。
|
